Skip to main content

Key Product Details

Species Reactivity

Human

Applications

Neutralization, Western Blot

Label

Alexa Fluor 750 (Excitation = 749 nm, Emission = 775 nm)

Antibody Source

Recombinant Monoclonal Mouse IgG1 Clone # 24822

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Product Specifications

Immunogen

E. coli-derived recombinant human CCL2/JE/MCP-1

Specificity

Detects human CCL2/JE/MCP-1 in Western blots. Does not cross-react with recombinant human (rh) CCL1, 3, 4, 5, 7, 11, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, rmCCL1, 2, 3, 4, 5, 6, 7, 9/10MIP-1 gamma, 11, 12, 17, 19, 20, 22, 24, 25, or rrCCL20.

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1

Applications for CCL2/JE/MCP-1 Antibody (24822) [Alexa Fluor® 750]

Application
Recommended Usage

Western Blot

Optimal dilutions of this antibody should be experimentally determined.

Neutralization

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Protein A or G purified from ascites

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: CCL2/JE/MCP-1

CCL2/JE/MCP-1, is a chemokine that binds the receptor CCR2 and induces the chemoattraction of mononuclear cells. It induces the activation of monocytes, NK cells, lymphocytes, and basophils. Additionally, CCL2 promotes Th2 polarization in CD4+ T cells, and CCL2-mediated recruitment of monocytes to sites of inflammation contributes to disease severity in atherosclerosis, multiple sclerosis, and allergic asthma. Endogenous proteolytic trimming of CCL2 at the N-terminus, including the N-terminal pyrrolidone carboxylic acid-modified glutamine, downregulates activity but not receptor binding.

Alternate Names

GDCF-2, HC11, HSMCR30, MCAF, MCP-1, SMC-CF

Gene Symbol

CCL2

Additional CCL2/JE/MCP-1 Products

Product Documents for CCL2/JE/MCP-1 Antibody (24822) [Alexa Fluor® 750]

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for CCL2/JE/MCP-1 Antibody (24822) [Alexa Fluor® 750]

Alexa Fluor (R) products are provided under an intellectual property license from Life Technologies Corporation. The purchase of this product conveys to the buyer the non-transferable right to use the purchased product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components, or any materials made using the product or its components, in any activity to generate revenue, which may include, but is not limited to use of the product or its components: (i) in manufacturing; (ii) to provide a service, information, or data in return for payment; (iii) for therapeutic, diagnostic or prophylactic purposes; or (iv) for resale, regardless of whether they are resold for use in research. For information on purchasing a license to this product for purposes other than as described above, contact Life Technologies Corporation, 5791 Van Allen Way, Carlsbad, CA 92008 USA or outlicensing@lifetech.com. This conjugate is made on demand. Actual recovery may vary from the stated volume of this product. The volume will be greater than or equal to the unit size stated on the datasheet.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...